Synthetic biology: at the crossroads of genetic engineering and human therapeutics - a Keystone Symposia report
Synthetic biology: at the crossroads of genetic engineering and human therapeutics - a Keystone Symposia report
Synthetic biology has the potential to transform cell- and gene-based therapies for a variety of diseases. Sophisticated tools are now available for both eukaryotic and prokaryotic cells to engineer cells to selectively achieve therapeutic effects in response to one or more disease-related signals, thus sparing healthy tissue from potentially cytotoxic effects. This report summarizes the Keystone eSymposium “Synthetic Biology: At the Crossroads of Genetic Engineering and Human Therapeutics,” which took place on May 3 and 4, 2021. Given that several therapies engineered using synthetic biology have entered clinical trials, there was a clear need for a synthetic biology symposium that emphasizes the therapeutic applications of synthetic biology as opposed to the technical aspects. Presenters discussed the use of synthetic biology to improve T cell, gene, and viral therapies, to engineer probiotics, and to expand upon existing modalities and functions of cell-based therapies.
98-117
Cable, Jennifer
637f3f7a-3719-4249-9b8d-3d2a187f23ea
Leonard, Joshua N.
05205230-2bb1-42fa-8336-ae0eebbc8331
Lu, Timothy K.
5c353d9a-8034-405e-a690-5da4ff7af1ee
Rackham, Owen J.L.
8122eb1f-6e9f-4da5-90e1-ce108ccbbcbf
16 November 2021
Cable, Jennifer
637f3f7a-3719-4249-9b8d-3d2a187f23ea
Leonard, Joshua N.
05205230-2bb1-42fa-8336-ae0eebbc8331
Lu, Timothy K.
5c353d9a-8034-405e-a690-5da4ff7af1ee
Rackham, Owen J.L.
8122eb1f-6e9f-4da5-90e1-ce108ccbbcbf
Cable, Jennifer, Leonard, Joshua N. and Lu, Timothy K.
,
et al.
(2021)
Synthetic biology: at the crossroads of genetic engineering and human therapeutics - a Keystone Symposia report.
Annals of the New York Academy of Sciences, 1506 (1), .
(doi:10.1111/nyas.14710).
Abstract
Synthetic biology has the potential to transform cell- and gene-based therapies for a variety of diseases. Sophisticated tools are now available for both eukaryotic and prokaryotic cells to engineer cells to selectively achieve therapeutic effects in response to one or more disease-related signals, thus sparing healthy tissue from potentially cytotoxic effects. This report summarizes the Keystone eSymposium “Synthetic Biology: At the Crossroads of Genetic Engineering and Human Therapeutics,” which took place on May 3 and 4, 2021. Given that several therapies engineered using synthetic biology have entered clinical trials, there was a clear need for a synthetic biology symposium that emphasizes the therapeutic applications of synthetic biology as opposed to the technical aspects. Presenters discussed the use of synthetic biology to improve T cell, gene, and viral therapies, to engineer probiotics, and to expand upon existing modalities and functions of cell-based therapies.
This record has no associated files available for download.
More information
Accepted/In Press date: 5 October 2021
Published date: 16 November 2021
Identifiers
Local EPrints ID: 501102
URI: http://eprints.soton.ac.uk/id/eprint/501102
ISSN: 0077-8923
PURE UUID: 0949609d-c68a-410b-8442-8bc0946445c1
Catalogue record
Date deposited: 23 May 2025 16:50
Last modified: 25 May 2025 05:14
Export record
Altmetrics
Contributors
Author:
Jennifer Cable
Author:
Joshua N. Leonard
Author:
Timothy K. Lu
Corporate Author: et al.
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics